

Quantitative TCR-seq

Unlock the secrets of immune diversity with our quantitative TCR-seq platform !

Whether your research focuses on the depths of immuno-oncology or tries to achieve breakthroughs in personalised medicine, our innovative techniques give you unrivalled insight into the dynamic world of immune repertoires.


Immuno-oncology has emerged over the past decade as an important breakthrough approach for cancer treatment. It aims at stimulating the patient's immune system by enhancing its natural ability to fight diseases.

Seqalis has developed a unique patented solution for the monitoring of the T-cell receptor (TCR) immune repertoires.


Named qTCR-seq, this unbiased quantitative technology platform makes it possible to explore and precisely characterise the immune response of T cells by sequencing the genes encoding TCRs.

The study of the T cells undoubtedly contributes to speed up the development of both new disruptive therapeutic drug candidates and related diagnostic approaches, e.g. the identification and the development of new biomarkers in the context of personalised medicine.

Why choose our qTCR-seq services?



Seamless qTCR-seq workflow from sample to result interpretation



Fostering Progress in Immuno-Oncology



CONTACT US TODAY TO FIND OUT MORE ABOUT OUR QTCR-SEQ SERVICES

